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ABSTRACT 
 
Background: Africa has the highest rate of Human Immunodeficiency Virus (HIV) infection and 
HIV associated nephropathy (HIVAN) is currently one of the most frequent paediatric kidney diseases 
observed in children. The most common form of glomerular damage exhibited by children is focal 
segmental glomerular sclerosis (FSGS) not otherwise specified according to the Columbia 
classification. HIVAN in children commonly presents as a form of nephrotic syndrome that often 
leads to end stage kidney disease (ESKD). Due to pathology of the kidney, proteins are excreted out 
into urine. The objective of this study was to determine the relationship between the urinary 
concentrations of albumin, β-2-Microglobulin (β2M) and Cystatin C proteins in children with HIVAN 
and idiopathic FSGS compared to HIV infected children with no kidney disease and healthy controls 
(HIV negative with no kidney disease). 
Methods:  Urine samples from 74 black South African paediatric subjects were analysed. The study 
group consisted of 34 children; HIVAN (n=14) and idiopathic FSGS (n=20). The control group 
consisted of 40 children; HIV positive (n= 20) and HIV negative (n=20) children - both with no 
kidney disease. Urine samples collected from all these children were stored at -80ºC. The urine 
samples were analysed for albumin, β2M and Cystatin C using the Bio-Plex Pro
TM
 RBM kidney 
toxicity assay.  Statistical analysis was performed using GraphPad Prism version 5. 
Results: The expression of urinary albumin was significantly different between idiopathic FSGS vs 
HIV positive and negative controls (p<0.0001 each). Similarly, urinary albumin was significantly 
dysregulated between HIVAN vs HIV positive and negative control groups (p=0.0206 and p=0.0056 
respectively). 
The excretion of urinary β2M proteins was significantly different in the HIVAN group compared to 
the HIV negative group (p= 0.0240). Urinary β2M levels were elevated albeit non-significantly in both 
HIVAN and idiopathic FSGS compared to control groups.  
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Urinary Cystatin C displayed a statistically significant increase in the idiopathic FSGS in comparison 
to both HIV negative (p= 0.0041) and HIV positive controls (p= 0.0256). Urinary Cystatin C 
expression was significantly low in the HIVAN group compared to idiopathic FSGS (p= 0.0150). 
However, no significance of Cystatin C was noted in the HIVAN group compared to HIV negative 
(p= 0.9860) and HIV positive control groups (p= 0.4311).  
Positive correlations were observed between albumin and Cystatin C (r = 0.6761), β2M and Cystatin 
C (r = 0.6596), albumin and βeta-2-microglobulin (r = 0.4220). 
Conclusion: Albumin significantly correlated with Cystatin C and β2M. Urinary β2M was significant 
between the HIVAN and HIV negative control groups. Urinary Cystatin C expression is significantly 
elevated in children with HIVAN and idiopathic FSGS. Therefore it may be a considered as a useful 
biomarker to detect kidney disease children. 
 
Key Words: HIV, FSGS, children, urinary proteins, albumin, biomarkers, Cystatin C, β2M. 
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BACKGROUND AND LITRATURE REVIEW 
 
1.1 HIV infection and chronic kidney diseases 
The association of Human Immunodeficiency Virus (HIV) infection and kidney syndromes was 
initially established  in the 1980’s (Kopp and Winkler, 2003). Globally, chronic kidney disease (CKD) 
is of great concern to public health, with an incidence of 1.5 - 3.0 million occurring in both children 
and adults (Fogo, 2007).  Patients that are HIV positive generally have a higher risk of proteinuria, 
albuminuria and low glomerular filteration rate (GRF) compared to those that are HIV negative 
(Shinha et al., 2015).   
The human immunodeficiency virus is a retrovirus, due to the viral RNA genome being reversely 
transcribed into DNA within targeted cells by using the reverse transcriptase viral enzymes. HIV-1 
belongs to the genus Lentivirus of the Retroviridae family (Ray, 2009).  
In 1982, 18 months after the incidence of the first case of HIV infection in adults, paediatric acquired 
immunodeficiency syndromes (AIDS) were established.  Paediatric HIV infections are the 
consequence of mother to child transmission occurring either in utero, via delivery or breast-feeding 
(Luzuriaga and Mofenson, 2016).  
The histopathological changes in HIVAN may differ between children and adults. And in studies 
among in paediatric populations it has been shown that the proportion of children with HIV-
associated nephropathy (HIVAN), that have collapsing glomerulopathy with FSGS, was approximate 
14% and 32.5% respectively. Further, it has been shown in biopsies, that with HIVAN in children, 
collapsing glomerulopathy may not always be present (Bhimma et al., 2013).   
By the end of 2011, it was estimated that 3.4 million children were infected with HIV and almost 91% 
of them were from Africa.  Africa has the highest rate - 70% of HIV infection compared to the rest of 
the globe. Even though Africa is considered to have 10% of the world’s population, it has the highest 
prevalence of HIV/AIDS in both paediatrics and adults (Bhimma et al., 2013).  
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By the end of 2013, 3.2 million children under 15 years of age globally had HIV infection, and 
240000 children were newly infected by this time (UNAIDS, 2014, Perazzo et al., 2015). Whereas in 
2010, the rate of HIV diseases displayed a slow decline in paediatric patients due to parents or 
children having greater access to treatment, in 2015 there were  nearly 150 000 new children infected 
with with HIV (Jindal et al., 2017). 
By 2016, an UNAIDS program had evaluated and overseen approximately 36.7 million people living 
with HIV in Africa. And, in the Eastern and Southern African regions, of an estimated 64% of them 
living with HIV infection, 160000 of these were children that were newly infected (UNAIDS, 2016). 
In an observation  in 1987  amongst 8 perinatally HIV infected babies who exhibited proteinuria and 
FSGS,  it was highlighted that the observation of kidney dysfunction in this population of babies 
could not have been due to iatrogenic causes (Pardo et al., 1987, Jindal et al., 2017). 
In-vitro studies have established the role of HIV-1 infection in kidneys. Efficient transfer of viral 
HIV-1 nucleic acids from the T cells to the kidney tubular epithelial cells has been shown (Bhimma et 
al., 2013). (Ramsuran et al., 2012) ultrastructually demonstrated HIV virions within podocytes 
implicating them as latent HIV reservoir. Moreover, injured glomerular podocytes may undergo 
proliferation and apoptosis and the remainder of podocytes enlarge in size, leaving segments of the 
basement membrane - and this supports the growth of sclerotic lesions that is characterized as HIVAN 
(Bhimma et al., 2013).    
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Figure 1: Renal Biospy, stained with hematoxylin and eosin dye, taken from a child with HIVAN 
(X150). Taken from (Ray, 2009). 
 
In the beginning HIVAN was initially viewed as a clinical and renal histopathological syndrome 
which was identified by the appearance of heavy proteinuria and speedy progression to ESKD (Ray, 
2009). HIVAN generally develops in patients that have severe immune-suppression with advanced 
HIV infection, and the cause of death is rarely related to renal diseases (Steel-Duncan et al., 2008). 
However HIV renal disease can occur at any stage of the infection (Bhimma et al., 2013). 
It is noted that HIV-1 and HIVAN in both adults and children are increasing over the years. However 
with the current treatment, using HAART, the survival rate in HIV infected persons has improved. As 
a consequence, in the long term, this treatment is causing secondary complications such as kidney and 
heart dysfunction and other long term complications (Soler-Palacín et al., 2011). Antiretroviral drugs 
that are frequently associated with renal toxicity are the following – Ritonavir (RTV), Lopinavir 
(LPV) and currently the Tenovir disproxil fumerate (TDF). Consequently the exposure to these drugs 
may be a contributing factor to complications of HIV - including kidney toxicity (Badiou et al., 2006, 
Soler-Palacín et al., 2011, Mocroft et al., 2010). 
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1.2 The structure of kidney  
A human body consists of two kidneys that weigh approximately 150g each, located in the 
retroperitoneal space (Briggs et al., 2009).  
 
Figure 2: A diagram showing the structure of a kidney. Adapted from (Julian et al., 2009). 
The nephron is the smallest structural and functional unit of the kidney, consisting of a renal corpuscle 
and a renal tubule. A kidney  consists of approximately one million nephrons (Briggs et al., 2009). 
The glomerulus is a tuft of capillaries, lying within the Bowman’s capsule. Water and low molecular 
weight constituents of plasma are filtered by the glomerular filtration apparatus which then passes into 
the renal tubules.  
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Figure 3: A diagram showing the structure of a glomerulus. Adapted from (Pollak et al., 2014). 
 
The filtrate passes through 3 layers ie. fenestrated endothelium, glomerular basement membrane and 
the podocytes and epithelial cells which embrace the capillaries. Filtration is based on charge and size 
of molecules, and hydrostatic pressure gradient across the membrane. The glomerular filtrate then 
enters the renal tubule where a selective reabsorption of water, inorganic ions and other molecules 
occur.  
The principal function of the kidney is to maintain water and electrolyte homeostasis. In most healthy 
patients these perturbations are rectified within hours, whereas in unhealthy patients, these 
perturbations and regulatory processes are disrupted, and may take longer to be rectified (Briggs et al., 
2009). 
Podocyte dysfunction is responsible for many renal diseases such as focal segmental 
glomerulosclerosis (FSGS), minimal change nephropathy, membranous glomerulonephritis and 
congenital nephrotic syndromes (Yu et al., 2016).  
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This abnormal functioning of the glomerulus often leads to chronic kidney diseases, the consequence 
which affects 5 to 10% of the population in many countries (Yu et al., 2016).  
 
1.3 Focal segmental glomerulosclerosis 
1.3.1 Definition   
Focal segmental glomerulosclerosis is a cause of nephrotic syndrome in children and adolescents, as 
well as a leading cause of kidney failure in adults, and children (Sharma et al., 2004, Eddy and 
Symons, 2003). FSGS  occurs due to podocyte injury from various causes  like circulating factors, 
viral infections and iatrogenic means (Rosenberg and Kopp, 2017).  It is the most common 
histopathological form of steroid resistant nephritic syndrome with a high propensity for progression 
to end stage kidney disease.  
1.3.2 Epidemiology  
The global incidence of FSGS across ethnicity has escalated over the past twenty years. In Africa the 
annual incidence of nephrotic syndromes (3.6) and FSGS (1.6) were considered to be significantly 
higher in Africans as compared to Caucasians (1.8 and 0.3 cases/10
5
 children per year) (Kiffel et al., 
2011). A study by McGrogan et al demonstrated a high incident rate of FSGS, ie from 0.25/100000 in 
females to 1.8/100000 in males per year (McGrogan et al., 2010). Women generally have a 1.5 fold 
lower incidence rate of FSGS  compared to men (Rosenberg and Kopp, 2017).  
FSGS is an aggressive disease.  About 30% - 40% of adult patients with FSGS progress to severe 
renal impairment within the first 10 years after onset of the disease (Fogo and Ichikawa, 1996, 
Silverstein and Craver, 2007). This however is different with children.  According to Abrantes et al, 
the chances of progression to severe renal insufficiency in paediatric FSGS was 8% at 5years, 17% at 
10yrs and 32% at 15yrs of age respectively (Abrantes et al., 2006).  Another study showed a high rate 
of progression to severe kidney dysfunction – especially in Black participants (Sorof et al., 1998, 
Silverstein and Craver, 2007). 
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1.3.3 Classification  
1.3.3.1 Primary/Secondary  
This disease can be divided into two categories - primary (idiopathic) and secondary. In the history of 
the development of FSGS it is known that approximately 30% to 60% of patients that are diagnosed 
with primary FSGS are most likely to progress to ESKD, over a period of 5 to 10 years (Kiffel et al., 
2011).  
a. Primary (idiopathic) FSGS occurs when there is no apparent etiology for renal 
histopathological result (Kiffel et al., 2011). It is generally known to be related to nephrotic-
range proteinuria, low albumin levels and hyperlipidemia. In some cases, primary FSGS is 
thought to arise due to a circulatory factor such as cytokines which make certain patients 
susceptible to disease, as occurs after kidney transplants. (Rosenberg and Kopp, 2017).  
b. Secondary FSGS on the other hand arises due to several casual agents which include – drugs 
(e.g. pamidronate), infections (e.g. HIV, Hepatitis B virus, parvovirus), lifestyle (obesity) or 
genetic mutations in podocyte proteins (Dettmar and Oh, 2016). Kidney biopsy findings that 
support the evaluation of secondary FSGS are the following – enlarged glomeruli, large 
number of perihilar scars indicating sclerotic changes and partial foot process effacements 
(Rosenberg and Kopp, 2017). 
 
1.3.3.2 Columbia classification of FSGS 
FSGS can be subdivided into 5 pathological variants (Figure 4) – collapsing (COLL), cellular 
(CELL), perihilar, glomerular tip lesion and not otherwise specified (NOS).  For the diagnosis of 
FSGS, the Columbia classification proposed a hierarchy, where the observation of the higher- ranking 
lesion reveals the clinical course - collapsing variant ˃ glomerular tip lesion ˃ cellular variant ˃ 
perihilar ˃ not otherwise specified (Stokes and D'Agati, 2014, Rosenberg and Kopp, 2017). The 
collapsing variant of FSGS exhibit segmental or global mesangial consolidation including the loss of 
endocapillary patency in association with the extracapillary epithelial enlargement and with or 
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without proliferation. The glomerular tip lesion generally affects the part of the glomerular tuft which 
is juxtaposed to the tubular pole. The prognosis of the cellular variant is still uncertain (Stokes et al., 
2006). The perihilar and not otherwise specified variants can be observed by either the segmental 
sclerosis or destruction of the capillary loops, with matrix increase involving the segment near the 
hilum (Rosenberg and Kopp, 2017).  
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Figure 4: The 5 histopathological variants of paediatric FSGS viewed at X200, adapted from (Shakeel et al., 2014).
                        
  
1 2
  A 
3 4 5 
A collapsing 
variant of FSGS 
stained with 
Silver. The 
segmental 
collapse of the 
capillary vessels 
with podocytes 
hyperplasia and 
hyperthropy.  
A perihilar variant 
of FSGS stained 
with Periodic 
Acid- Schiff. 
Sclerosis is 
observed at the 
perhiliar region.   
 
 
FSGS not 
otherwise 
specified stained 
with Sliver.       
Segmental 
glomerulosclerosis 
with more than 
50% of the 
glomerulus 
sclerosed and 
adhering to 
Bowman’s capsule.  
A glomerular tip 
lesion, involving 
the tubular pole, 
is a variant of 
FSGS. Here it is 
stained with 
Periodic Acid-
Schiff.  
A cellular variant 
of FSGS stained 
with Periodic 
Acid-Schiff.  
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1.4 Diagnosis and Evaluation of FSGS 
The examination of whether a patient has FSGS solely depends on kidney biopsies. The use of 
immunfluorescene analysis, electron microscopy and various staining techniques are crucial in the 
diagnosis, understanding and determining FSGS and other renal disorders such as minimal change 
disease (Rosenberg and Kopp, 2017).   
FSGS is diagnosed by kidney biopsies which provides information on diseases and histopathological 
abnormalities (Giorgi, 2016). The biopsy can be conducted either surgically or percutaneously. This 
procedure may have several limitations - it is invasive, and has the possibility of internal damage to 
adjacent organs or tissue or even the kidney itself.  There is also a danger of bleeding in certain 
patients which could be fatal - with a frequency of approximately 0.1% (Zollinger and Mihatsch, 
2012). Another serious complication is infection. Any one of the above would definitely drive up the 
cost of the procedure – which is in itself is a limiting factor in a resource limited setting.  
Therefore non-invasive techniques such as biomarkers should be investigated as an alternative for the 
diagnosis of kidney diseases including FSGS. 
 
1.5 Biological Biomarkers 
A biomarker is generally described as a characteristic that can be identified, measured and evaluated 
as an indicator of biological processes in response to different therapeutic interventions (Al-Ismaili et 
al., 2011).  
Biomarkers can also possibly be used as surrogate end-points. However in paediatric studies and 
research, end-points are usually difficult or take extensive periods of time to confirm findings. The 
use of biomarkers are therefore viable alternatives. The expression and observations of biomarkers 
may result from either down-regulated or up-regulated genes or proteins in the kidney due to different 
mechanisms of renal tubular cell damage (Al-Ismaili et al., 2011).  
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Sensitivity and specificity are used to determine accuracy of results.  The advantage of using urine as 
a biomarker is due to its easy accessibility. It is also non-invasive and  correlates with kidney damage, 
and may also reflect certain aspects of the renal cycle (Tony et al., 2016).  
Overall a good biomarker should have the following properties – easy accessibility, non-invasiveness 
and be measured using standardized assays with rapid results, including an  affordable cost for 
experiments to be executed (Al-Ismaili et al., 2011). They should also have high sensitivity and high 
specificity.  
 
1.5.1 Albumin Proteins    
Albumin is a water soluble protein, anionic and is  heart shaped molecule with a molecular weight of 
65 kDa, that is synthesised in the liver (Friedman and Fadem, 2010). In humans, 170mg to 9g of  
albumin is synthesised daily (Birn and Christensen, 2006). 
It plays a role in the transport of a variety  of circulating molecules, as a carrier of metabolites, 
hormones, drugs, vitamins, as an acid and base buffer, antioxidant functions and also by maintaining 
the oncotic pressure and volume of blood plasma (Birn and Christensen, 2006).  
Several studies have confirmed that albumin and its ligands causes the expression of inflammatory 
and fibrogenic mediators. It is assumed that the escalated filtration of albumin may result in excessive 
tubular reabsorbtion leading to inflammation and fibrosis, eventuating in a loss of renal function (Birn 
and Christensen, 2006).  
The loss of albumin in the urine is considered to be an outcome of the imbalance between both 
glomerular filtration and tubular reabsorbtion. However both serum an urinary albumin levels are 
crucial prognostic indicators in many renal diseases (Birn and Christensen, 2006).   
The integrity of the glomerular membrane determines whether albumin or other proteins will be 
excreted (Eknoyan et al., 2003, Abitbol et al., 2006). Albuminuria arises when higher than normal 
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amounts of albumin is excreted in both children and adults, and it is confirmed if it persists up to 3 
months (Julian et al., 2009). 
Because there may be false positives as well as false negatives on the dipstix test, a more accurate 
means of testing would be to analyse a 24hour urine sample for the quantification of albumin 
excretion by calculating the protein/creatinine ratio (Julian et al., 2009). The ratio above 3.5 (mg/mg) 
may be considered albuminuria. A ratio below 0.2 is considered normal in healthy people (Ginsberg et 
al., 1983). Patients that have albuminuria generally excrete 30 – 300 mg of albumin daily (Mudi et al., 
2014), and in severe cases, urinary albumin up to 3g is excreted (Julian et al., 2009).   
Albuminuria has been investigated in many diseases like - sickle cell, hypertension, HIV and diabetic 
nephropathy (McKie et al., 2007, Mudi et al., 2014). Albuminuria is considered to be precursor of 
HIV associated kidney diseases (Fabian, 2007, Mudi et al., 2014). 
 
 
 
Figure 5: Mechanisms of albumin induced progression to the loss of renal function, taken from 
(Roscioni et al., 2014). 
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1.5.2 βeta-2-microglobulin 
βeta-2-microglobulin (β2M) proteins were first isolated in 1964 from urine of patients with Wilsons’s 
disease. These proteins are indicators of kidney diseases, and they are also non- specific markers for 
other diseases such as autoimmune diseases, malignancies and especially in Acquired Immuno-
deficiency Syndromes (AIDS) (Bethea and Forman, 1990).  
β2M is a polypeptide which forms the beta chain of the human leukocyte antigen (HLA) class 1 
molecules, and its structure is 7-stranded β-pleated (Drüeke and Massy, 2009). Since these β2M 
proteins have a low molecular weight (11 kDa), they pass through the glomerular membrane. These 
occur on most surfaces of nucleated cells and in greater parts of biological fluids, urine, synovial 
fluids and including serum (Drüeke and Massy, 2009).  
Serum levels of β2M are enhanced in several chronic inflammatory conditions, including rheumatoid 
arthritis, systemic lupus, in viral infections such as infectious mononucleosis, non A non B hepatitis, 
cytomegalovirus and AIDS (Bethea and Forman, 1990).  
The standard β2M serum concentration in the human body is approximately 1.5 – 3 mg/l, whereas the 
average normal production rate is estimated to be 2.4mg/kg/day. However in unhealthy patients that 
have ESKD, the β2M levels are generally higher than normal concentration  [20-50mg/l to 100mg/l] 
(Drüeke and Massy, 2009).  
It is endocytosed by the proximal convoluted tubular cells and then catabolised into amino acids. 
These proteins are thus useful predictors of renal function especially in kidney transplant recipients 
and in those that are thought to have tubule-interstitial diseases (Bethea and Forman, 1990).  
Serum β2M is used to monitor changes in GFR. The urinary β2M excretion of greater than 370μg/ 
24hours reflects tubular dysfunction. However urinary assays are challenging since  β2M molecules 
degrade easily at pH ˂ 6 (Bethea and Forman, 1990).  
In healthy neonates, these molecules are filtered by the glomeruli, of which 99.9% is reabsorbed by 
the proximal convoluted tubules. The presence of increased plasma levels of β2M can be observed in 
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those with kidney failure or tumours. Therefore a high concentration of β2M molecules may serve as a 
sensitive biomarker for kidney disease (Chaudhary et al., 2016).  
 
Figure 6: Diagram showing the production and excretion of β2M, adapted from (Keown, 2013).  
 
1.5.3 Cystatin C  
Cystatin C is a plasma protein (13 kDa) that is produced by all nucleated cells in the human body. It 
functions as the cysteine protease inhibitor (Dajak et al., 2010). The production of cystatin in the body 
is independent of age, gender and muscle mass. Some studies indicate that the changes in cystatin 
levels may contribute in the detection of renal failure (Bang et al., 2017).  
These molecules are non-glycosylated, belonging to the type II cystatin gene family and is secreted 
after synthesis (Robles et al., 2017). Cystatin C molecules are filtered and entirely reabsorbed which 
is then broken down in the proximal tubules, and its levels are low in the urine whilst the levels 
remain relatively unchanged in the blood (Deyà-Martínez et al., 2016). In patients with kidney 
transplant, diabetes and CKD Cystatin C is found much earlier in the urine than creatinine. These 
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plasma proteins are known to protect the connective tissue from injury of intracellular enzymes 
emanating from  cell death or secreted by malignant cells (Deyà-Martínez et al., 2016).   
The estimation of glomerular filtration rates (GFR) is vital for the examination and follow up of 
patients with kidney diseases (Alberer et al., 2017). The measurements of Cystatin C is believed to be 
of better prognostic value than to creatinine for GFR assessment, especially in patients with advanced 
kidney disease who have a GFR below 60 ml/min/1.73  . And it has been successfully demonstrated 
in children with kidney disorders caused by various conditions (Deyà-Martínez et al., 2016). The level 
of Cystatin C remains persistent after the first few years of life, from the age of 4 months to 70 years 
(Beegum et al., 2017). 
Studies have shown that these molecules can be used as sensitive biomarkers for acute kidney failure 
and diseases. Urinary and serum Cystatin C concentrations are closely associated to kidney functions. 
However when kidney injuries occur these proteins are elevated. It is considered that in tubular 
disorders, these proteins would be degraded and consequently be observed in the urine (Robles et al., 
2017).   
There are multiple studies with evidence indicating that the analyses of cystatin could be used as a 
tool for the detection of HIV infected patients who are at risk for kidney disorders, coronary artery 
diseases (CVD)  and  cancer (Yanagisawa et al., 2015).  
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Figure 7: The manifestation of Cystatin C in urine may possibly be an indiaction of renal damage, 
adapted from (Malyszko et al., 2015). 
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1.6 Aim and Objectives  
Aim  
The aim of this study was to determine if albumin, β Microglobulin and Cystatin C could be used as 
urinary biomarkers for the detection of focal segmental glomerulosclerosis in children. 
Objectives 
1. To compare the levels of albumin, β M and Cystatin C in children with biopsy proven FSGS to 
healthy controls.  
2. To measure and compare the levels of albumin, β M and Cystatin C in FSGS according to HIV 
status. 
3. To compare the levels of albumin, β M and Cystatin C in FSGS and HIV- associated FSGS to 
HIV positive children with no kidney disease and healthy controls. 
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Abstract  
Background: Africa has the highest rate of Human Immunodeficiency Virus (HIV) infection and 
HIV associated nephropathy (HIVAN) is currently one of the most frequent paediatric kidney diseases 
observed in children. The most common form of glomerular damage exhibited by children is focal 
segmental glomerular sclerosis (FSGS) not otherwise specified according to the Columbia 
classification. HIVAN in children usually presents as a form of nephrotic syndrome that often leads to 
end stage kidney disease (ESKD). Due to abnormal kidney functioning, proteins are excreted out into 
urine. The objective of this study was to determine the urinary concentrations of β-2-Microglobulin 
(β2M) and cystatin C proteins in children with HIVAN and idiopathic FSGS compared to HIV 
infected children with no kidney disease and healthy controls (HIV negative with no kidney disease). 
Methods:  The study group comprised of 34 children; 14 with HIVAN and 20 with idiopathic FSGS. 
The control groups were 20 HIV positive and 20 HIV negative children with no kidney disease. Urine 
samples collected from these 74 children were stored at -80ºC. Bio-Plex technology was used to 
analyse urinary protein concentration of cystatin C and β2M.  
Results: A significant increase in urinary β2M levels was observed in the HIVAN group compared to 
the HIV negative group (p= 0.0240). High statistical significance was noted in urinary cystatin C 
excretion in the idiopathic FSGS compared to both HIV negative (p= 0.0041) and HIV positive 
controls (p= 0.0256).  Urinary cystatin C displayed a significant decrease in the HIVAN group 
compared to idiopathic FSGS (p= 0.0150). However, no significance of cystatin C was noted in the 
HIVAN group compared to HIV negative (p= 0.9860) and HIV positive control groups (p= 0.4311). 
Conclusion: Urinary cystatin C levels are significantly elevated in children with HIVAN and 
idiopathic FSGS. It may be a useful biomarker to detect kidney disease in children. 
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Introduction  
Africa has the highest incidence of Human Immunodeficiency Virus (HIV) infection, affecting 
approximately 36.7 million people [1]. Moreover, 2.1 million children (<15years) are HIV infected 
with a further 160 000 being newly infected annually [1]. Currently 3.4 million children are infected 
with HIV with 91% of these infections occurring in Africa [2].  Notably, a 50% decrease in new 
paediatric HIV infection are reported due to access to antiretroviral therapy (ARV) [3]. Globally 
kidney disease is rapidly becoming a major public health concern as a cause of morbidity and 
mortality in children. Kidney disease in the setting of HIV that is untreated often leads to rapid 
progression to end stage kidney disease [4].  
In one the largest paediatric studies in Africa, Ramsuran et al, reported  that nephrotic syndrome due 
to HIV-associated nephropathy is the commonest form of kidney disease in the setting of HIV seen 
in childhood [4]. The prevalence of HIVAN has increased in both adults and children [5]. (Soler-
Palacín et al., 2011). Previous studies in paediatric populations have indicated that the proportion of 
children with HIVAN, was approximately 32.5% [2, 4]. 
Focal segmental glomerulosclerosis is a cause of nephrotic syndrome and the most common 
histopathological form of steroid resistant nephrotic syndrome  in children and adolescents, with a 
high propensity for progression to ESKD [6]. Approximately 30% to 60% of patients that are 
diagnosed with primary FSGS are most likely to progress to ESKD, over a period of 5 to 10 years [7].  
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Whilst a kidney biopsy is the gold standard for providing histopathological assessment of the type of 
pattern of kidney disease, it is an invasive procedure with attendant complications such as bleeding, 
infection, visceral perforation or fistula formation. Currently, non-invasive strategies for detection and 
monitoring the effect of kidney diseases in children include the utility of creatinine levels [8, 9]. 
However, several factors are posed against it, as these values are influenced by protein intake, 
nutritional status, muscle mass and body weight, all of which are affected in HIV-infected children 
and nephrotic syndromes.  Hence the use of a non-invasive biomarker to detect kidney disease is 
urgently warranted [10]. 
β2M proteins are freely filtered in the glomeruli and are reabsorbed and metabolized in the proximal 
tubule. Although urinary excretion of β2M it is an indicator of underlying kidney disease, it is non-
specific as increased urinary excretion may occur in other diseases such as autoimmune diseases, 
malignancies and especially in Acquired Immuno-deficiency Syndromes (AIDS) [11]. There is 
however a lack of data on the efficiency of β2M as a biomarker for various forms of kidney diseases. 
Cystatin C is a 13kDa plasma protein that functions as a cysteine protease inhibitor [12], and its 
dysregulation has been implicated in the detection of impaired kidney function [13]. In patients with 
kidney transplant, diabetes and CKD Cystatin C is found much earlier in the urine than creatinine. 
The measurements of Cystatin C is believed to be of better prognostic value than to creatinine for 
GFR assessment, especially in patients with advanced kidney disease who have a GFR below 60 
ml/min/1.73. This has successfully been demonstrated in children with kidney disorders caused by 
various conditions [14].  
In an attempt to evaluate the accuracy of β2M and Cystatin C as predictors of kidney disease in HIV- 
infected children, notably HIVAN, we compared and contrasted the urinary levels of β2M and 
Cystatin C in children with HIVAN and idiopathic FSGS to a control group of children (HIV positive 
and HIV negative with no kidney disease).   
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Methods  
Study design  
Ethical permission to conduct this study was obtained from the Biomedical Research Ethics 
Committee of the College of Health Sciences, University of KwaZulu-Natal, (BREC reference: 
BE202/17). Urine samples were collected from children attending the Inkosi Albert Luthuli Central 
Hospital and King Edward VIII Hospital in Durban, KwaZulu-Natal, South Africa. Informed consent 
was obtained from the parent or guardian and assent (where applicable) from the patient prior to 
collection of urine samples. Samples were collected 2-4 years after the kidney biopsy was done, 
aliquoted and stored in cryovials at -80ºC for a period of approximately 3 months until analysed.  
Study population  
Seventy four Black South African children aged 1 - 16 years were recruited. The study group (n = 34) 
consisted of children with biopsy proven HIVAN (n = 14) and idiopathic FSGS (n =20). At the time 
of sample collection none of the children had fever or any other evidence of secondary infections. In 
children with HIVAN co-morbidities included cardiomyopathy (n = 6), chronic lung disease (n = 4) 
and stunting (n = 4). The control group (n= 40) consisted of children who were HIV positive with no 
kidney disease (n = 20) and HIV negative with no kidney disease (n = 20). The HIV negative children 
with no kidney disease were recruited from follow-up clinics e.g. neurology, endocrine and 
respiratory clinics.  
Prior to recruitment, all 14 children with HIVAN were on cART and angiotension converting enzyme 
antagonists for a minimum of 2 years. At the time of sample collection the 20 children with idiopathic 
FSGS were on lose dose steroids, angiotensin converting enzyme inhibitors as well as additional 
immunosuppressants such as calcinuerin inhibitors.  
Diagnosis of HIVAN   
The classification of HVAN was based on the confirmation of HIV- 1 infection and presence of 
persistent proteinuria of  ≥1+ on urinary dipsticks examination with one or more of the following (i) 
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abnormal urinary sediment; (ii) presence of enlarged echogenic kidney by renal ultrasound; (iii) 
histological findings of FSGS; (iv) microcystic dilation, a childhood variant of HIVAN in the absence 
of significant podocyte lesions [4, 15].  
Bioplex Multiplex  
The urine samples were analysed for β2M and cystatin C using the Bio-Plex Pro
TM
 RBM kidney 
toxicity assay (panel 2) (Bio-Rad Laboratories, Inc., USA) according to manufacturer’s instructions 
[16]. 
The detection of reaction was carried out using the Bio-Plex
® 
MAGPIX
TM
 200 reader system (Bio Rad 
Laboratories Inc, 2017).  Raw data was collated using a Bio-Plex Manager
TM 
software version 4.1. A 
standard curve was generated using the known concentration (ng/ml) of each anlayte by plotting the 
median fluorescent intensity (MEI) signal against concentration. These standards were used to 
interpolate the concentration of the unknown samples. Intra-plate variablilty were determined with 
CV <20% and (X100) between 70-130% (r=0.8, p=0.05). All data was imported to an Excel 
spreadsheet for statistical analysis. 
Statistical Analysis   
Non parametric tests (Mann-Whitney U) were performed for statistical analysis using GraphPad 
Prism version 5 (GraphPad software version 5, San Diego California, USA). One-way ANOVA and 
the Dunns post hoc multiple comparison test were used. Spearmans coefficients were used to evaluate 
correlations. The level of statistical significance was considered as p ˂ 0.05.  Graphical data 
represented as median and interquartile range. 
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 Results  
Fourteen children (19%) were HIV positive and were confirmed paediatric HIVAN and 20 children 
(27%) had idiopathic FSGS, all with FSGS had histopathological pattern of FSGS not otherwise 
specified.  The mean age for HIVAN and idiopathic FSGS was 10 ± 3.62 (range: 6.00 – 19.00) and 9 
± 3.11 (range: 4.00 – 13.00) years respectively (Table 1).The control groups consisted of 40 children 
with no kidney disease; 20 (27%) children were HIV negative with a mean ± SD age of 7 ± 3.87 
(range: 2.00 – 14.00) years and 20 (27%)  children HIV positive with a mean of 11 ± 3.52 (range: 5.00 
– 15.00) years.  
The patients with known FSGS had stages 1 and 4 CKD according to the KDIGO classification [9]. In 
the idiopathic FSGS group 11 patients had CKD stage 1; 4 stage 2; 2 stage 3; and 3 stage 4. In the 
HIVAN group 8 patients were CKD stage 1, 1 stage 2, 3 stage 3 and 2 stage 4. These patients were 
diagnosed with FSGS for a mean of 2.8 years with a range of 2.1-4.3 years prior to study entry. 
Kidney biopsy showed FSGS (not otherwise specified) in all patients with over 80% of glomeruli 
having more than 50% sclerosis.  
To determine the association with the variability, we compared urinary protein concentration of β2M 
and Cystatin C with age, weight, creatinine, urine creatinine, eGFR, urea, albumin and cholesterol in 
the four groups of children. No statistical significant correlation was observed in β2M and Cystatin C 
when compared to the above clinical and biochemical findings. This indicates that these factors had 
no major impact on the concentration of these urinary proteins in children.  
Urinary concentrations β2M and Cystatin C 
The urinary concentration of β2M and Cystatin C as displayed in Figures 1a and 1b, respectively.  
A statistical significant increase was observed in urinary β2M excretion in the HIVAN (mean = 169.7 
ng/ml; 95% CI: 272.3-67.15) group compared to the HIV negative control (mean = 52.15ng/ml; 95% 
CI: 75.19-29.10) (Mann Whitney U= 75.00; p= 0.0240). No other statistical significant differences of 
urinary β2M concentrations were noted across the study groups (Table 2). 
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There was a significant increase of Cystatin C in the idiopathic FSGS group (mean = 987.7 ng/ml; 
95% CI: 1689-286.7) compared to HIV negative control group (mean = 87.49 ng/ml; 95% CI: 144.0-
30.97) (Mann-Whitney U= 93.50; p= 0.0041). There was also a significant decrease in the HIVAN 
group (mean = 203.5 ng/ml; 95% CI: 400.5-6.522) compared to the idiopathic FSGS group (mean = 
987.7 ng/ml; 95% CI: 1689-286.7) (Mann-Whitney U= 70.00; p=0.0150). Once again a statistical 
significant increase in idiopathic FSGS groups (mean = 987.7 ng/ml; 95% CI: 1689-286.7) compared 
to the HIV positive control (mean = 104.5 ng/ml; 95% CI: 152.5-56.41) (Mann Whitney U= 117.0; p 
= 0.0256). 
Cystatin C levels were down-regulated in the HIVAN group (mean = 203.5 ng/ml; 95% CI: 400.5-
6.522) compared to the HIV negative control group (mean = 87.49 ng/ml; 95% CI: 144.0-30.97) 
however, this did not reach a statistical significance (Mann-Whitney U= 139.0; p= 0.9860). A non-
significant decrease (Mann Whitney U= 117.0; p= 0.4311) was observed in the HIVAN group (mean 
= 203.5 ng/ml; 95% CI: 400.5-6.522) compared to the HIV positive control group (mean = 104.5 
ng/ml; 95% CI: 152.5-56.41).  
The expression of urinary albumin was significantly different between idiopathic FSGS (mean= 
135400 ng/ml; 95%CI: 170700-100100) compared to HIV negative (mean = 15380 ng/ml; 95%CI: 
35860- -470.6; p < 0.0001). A statistical significance of albumin was observed in idiopathic FSGS 
(mean =135400 ng/ml; 95% CI: 170700-100100) compared to HIV positive (mean = 17690 ng/ml; 
95% CI: 35860- -470.6; p < 0.0001). Urinary albumin was also significant in HIVAN (mean = 86530 
ng/ml; 95% CI: 135500-37600) compared to HIV positive control (mean = 17690 ng/ml; 95% CI: 
35860- -470.6; p = 0.0206). Similarly, urinary albumin was significantly dysregulated between 
HIVAN (mean = 17690 ng/ml; 95% CI: 35860- -470.6) compared to negative control groups negative 
(mean = 15380 ng/ml; 95%CI: 35860- -470.6; p = 0.0056) (Figure 2).  
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Figure 1(a): The urinary concentration of β2M in HIVAN, idiopathic FSGS, HIV negative and HIV 
positive control groups. Results are represented by median and interquartile range. *The concentration 
of β2M is significantly different between HIVAN and HIV negative controls, p=0.0240. 
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Figure 1(b): The urinary concentration of Cystatin C in HIVAN, idiopathic FSGS, HIV positive, and 
HIV negative control groups. Results are represented by median and interquartile range. *Urinary 
concentration of Cystatin C is significantly different between idiopathic FSGS and HIV negative 
controls, p=0.0131; **idiopathic FSGS and HIV positive controls, p= 0.0256; and *** HIVAN and 
idiopathic FSGS, p= 0.0150.  
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Figure 2: The urinary concentration of albumin in HIVAN, idiopathic FSGS, HIV positive, and HIV 
negative control groups. Results are represented by median and interquartile range. *Urinary 
concentration of albumin is significantly different between idiopathic FSGS and HIV positive p < 
0.0001; **idiopathic FSGS and HIV negative controls, p < 0.0001; ***HIVAN and HIV negative p = 
0.0056; ****HIVAN and HIV positive controls, p = 0.0206. 
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Table 1: Clinical and laboratory demographics of patients, expressed as mean ± standard deviations. 
 
 
  
Sample Groups 
 
HIV Negative 
Control 
n = 20 
HIV Positive  
Control 
n = 20 
Idiopathic FSGS 
n = 20 
HIVAN 
n = 14 
Sex (Male/Female) Male Male Male Male 
Age  (years) 7 ± 3.87 11 ± 3.25 9 ± 3.11 10 ± 3.62 
Weight (kg) 18.20 ± 10.55 37.25 ± 13.73 29.04 ± 10.33 31.13 ± 11.57 
Creatinine (mol/l) 29.14 ± 9.25 40.10 ± 9.25 45.32 ± 15.44 82.83 ± 62.36 
Urine Creatinine (mmol/l) 2.38 ± 0.42 - 6.71 ± 4.50 4.05 ± 2.68 
Protein  1.85 ± 0.67 - 4.22 ± 4.21 3.07 ± 2.04 
eGFR (ml/ min /1.73m) 218.00±122.01 207.13±58.02 125.09±102.53 119.98±57.84 
Urea blood (mol/l) 2.71 ± 1.58 5.34 ± 9.81 7.64 ± 7.02 5.30 ± 4.26 
Albumin (mg/dl) 29.91 ± 14.76 28.96 ± 7.96 30.77 ± 10.94 37.30 ± 9.25 
Cholesterol (mmol/l) - 3.75 ± 0.68 8.21 ± 4.80 4.82 ± 2.36 
CD4 count  900.60±620.00 - 820.20±642.10 
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Table 2: The mean concentration of β2M and cystatin C in study groups versus controls. 
 Comparison Mean(ng/ml) (95% CI: upper and lower) Mann Whitney U P value 
β
2
M
 
HIVAN vs HIV negative control  169.7(272.3- 67.15) vs 52.15 (75.19- 29.10) 75.00 0.0240* 
HIVAN vs HIV positive control 169.7(272.3- 67.15) vs 85.94(143.5-24.34)  88.0 0.0715 
Idiopathic FSGS vs HIV negative control 383.1 (605.3-161.0) vs 52.15(75.19- 29.10)  138.0 0.0962 
Idiopathic FSGS vs HIV positive control 383.1 (605.3-161.0) vs 85.94(143.5-24.34) 144.5 0.1367 
HIVAN vs Idiopathic FSGS  169.7 (272.3- 67.15) vs 383.1(605.3-161.0) 140.0  0.9860 
 
C
y
st
at
in
 C
 
HIVAN vs HIV negative control  203.5 (400.5-6.522) vs 87.49 (1440- 30.97) 139.0 0.9860 
HIVAN vs HIV positive control 203.5 (400.5- 6.522) vs 104.5 (152.5-56.41)  122,0 0,1600 
Idiopathic FSGS vs HIV negative control  987.7 (1689-286.7) vs 87.49 (144.0- 30.97) 93.50 0.0041* 
Idiopathic FSGS vs HIV positive control 987.7 (1689-286.7) vs 104.5 (152.5-56.41)  117.0 0.0256* 
HIVAN vs Idiopathic FSGS  203.5 (400.5-6.522) vs 987.7(1689-286.7) 70.00 0.0150* 
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Discussion  
In this study, we report on two candidate biomarkers (β2M and Cystatin C) in HIVAN (all presenting 
as classical variants of FSGS on histopathology) and idiopathic FSGS compared to HIV positive and 
negative controls.  
The expression of urinary β2M was significantly upregulated in HIVAN as compared to HIV negative 
control groups but was not so when comparing HIVAN to HIV positive controls or idiopathic FSGS. 
A study by Nishijima et al, reported high levels of β2M and α1M as biomarkers in the detection of 
kidney tubulopathy in patients with HIV-1 infection [17]. The latter study however, was not FSGS 
related. A study conducted by Garcia et al, reported an increase in β2M in urine  of children with 
HIVAN [18].  
Of note, in kidney disease, urinary β2M is generally elevated, reflecting tubular dysfunction [19]. In 
healthy individuals, due to the low molecular mass of these proteins, they are easily filtered through 
the glomerular filtration apparatus, and are reabsorbed in the proximal convoluted tubules [19]. These 
results indicate that the upregulation of β2M noted in our study may be attributed to either abnormal 
glomerular filtration, or tubular dysfunction in children with HIVAN. In idiopathic FSGS there is also 
tubular involvement to varying degrees [20]. But it is possible that the degree of tubular dysfunction 
may not have been sufficient in our group of patients to show significant differences between this 
group and healthy controls. A study by Kim and Lim, reported higher levels of β2M in children with 
FSGS [21]. This finding may be attributed to proximal convoluted tubular pathology where they are 
unable to absorb and transfer β2M back into the interstitial capillaries and into the general circulation. 
Donadio, reported a significant elevation of urinary β2M concentrations in patients with chronic 
kidney disease at stage 4 and 5 [22]. It is also documented that high β2M is evident in kidney 
infection, chronic kidney failure and various connective tissue diseases [19]. Also, this outcome in our 
study may be due to the small sample size that was used, making it difficult to detect significant 
differences across the groups. 
35 
 
In our study we also report a statistical significant increase of urinary Cystatin C concentration in 
idiopathic FSGS group compared to the HIV negative control group, as well as the idiopathic FSGS 
compared to the HIV positive control group.  
 
In a study on lupus nephritis, a condition that causes glomerular injury similar to FSGS, Tony et al, 
observed a significant increase of urinary Cystatin C excretion in patients with lupus nephritis 
compared to controls [23]. Further, Donadio reported a significant elevation of urinary Cystatin C 
concentrations in patients with CKD at stage 4 and 5, compared to individuals with normal GFR [22]. 
These findings on elevated Cystatin C excretion were similar to our study. Urinary Cystatin C 
proteins are known to protect tissues and cells from damage due to intracellular enzymes released 
from apoptosis or malignancy. However, when glomerular sclerosis is present, the levels of Cystatin 
C may increase [14], as was observed in our study. 
We report a dysregulation, specifically a significant down regulation of urinary Cystatin C levels in 
the HIVAN group compared to the idiopathic FSGS group. In contrast to our study, elevated levels of 
Cystatin C in the urine of HIV-infected children with proteinuria have been reported by Garcia et al, 
suggesting a compromised capacity of the proximal tubular epithelial cells to reabsorb and metabolize 
Cystatin C in these patients [24, 25]. This apparent contradiction with our study may also be 
explained by a discordance between immunological and clinical stage of the HIV disease [26]. 
 
Nonetheless, in one study, serum Cystatin C, which reflects renal dysfunction directly correlated with 
HIV viral load [26]. On the other hand, patients with a very low viral load, including those receiving 
kidney transplants, may also develop HIVAN [25].  Further, even though Cystatin C is a potent 
marker for inflammation and kidney disease, it has also been shown to have antiviral activity [27, 28]. 
It is plausible, that in HIV infected patients, as in our cohort, there may have been a downregulation 
of serum Cystatin C due to its interaction with the virus, and hence low urinary Cystatin C excretion.  
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The limitations of our study were sample size and absence of viral load, hence we were not able to 
correlate our data with the severity of HIV infection. Future investigations should also consider an 
assessment of nutritional state. 
 
Conclusion  
This study demonstrates highly significant levels of urinary Cystatin C expression. However, β2M 
was only significantly different between HIVAN and the HIV negative controls. Therefore only 
urinary Cystatin C proteins may be considered a suitable biomarker for the non invasive testing in the 
early detection of idiopathic and HIV – associated FSGS in paediatric subjects. 
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Synthesis 
Children may have a range of chronic and acute diseases complicated by HIV-infection.  Chronic 
kidney disease may be caused by the virus itself, and this may take a form of HIVAN or HIV – 
associated immune complex kidney disease (HIVICK) (Samarawickrama et al., 2012). FSGS is a 
histopathological diagnosis that is made on kidney biopsy (Jindal et al., 2017, Giorgi, 2016). With the 
progression of time, the immune system becomes further compromised in HIV individuals, many 
develop end stage kidney disease (ESKD), and  other co-morbidities such as diabetes and 
hypertension (Samarawickrama et al., 2012). It is very important that the correct diagnosis is made as 
early as possible so that appropriate treatment may be effected to halt the progression to ESKD 
(Herrero-Morín et al., 2007). In a resource poor settings,  biopsy of the kidney is often delayed (Ekulu 
et al., 2016). Therefore, urinary biomarkers for FSGS may present an excellent opportunity to either 
guide the healthcare practitioner to motivate for a biopsy, or to offer the patient empirical treatment 
where the biopsy cannot be done. 
Albumin excreted via the kidney glomeruli are generally reabsorbed back into the renal tubules. 
However, trace amounts of albumin may be found in the urine due to lack of  tubular capacity 
(Samarawickrama et al., 2012). In patients with HIVAN or HIVICK, the glomerular structure is 
damaged.  This has a major impact on filtration and reabsorption of proteins. Therefore, higher 
concentrations of albumin are released in urine. This manifestation in children and adults is referred to 
as albuminuria (Samarawickrama et al., 2012).  
The upregulation of albumin proteins in our study demonstrates a significant difference between the 
FSGS in contrast to controls. A previous study, reported that albuminuria in school children was 
significantly associated with ESKD (Lin and Huang, 2016). Similarly, Fredrick (2012), also observed 
high albuminuria rates in children (Fredrick et al., 2012). Despite varying methods, Ikpyme et al, 
report that urine albumin/creatinine ratio, (p = 0.03), could be used for the early detection for HIVAN 
(Ikpeme et al., 2012). Hence, in a resource restricted environment such as KwaZulu-Natal, such a test 
could be useful for HAART initiation.   
42 
 
Notwithstanding, albuminuria being an established finding in nephrotic syndrome, we demonstrated a 
correlation across the proteins where β2M and Cystatin C accurately predict the same diagnosis.  
In relation to albumin and β2M we found that there was a significant correlation (r = 0.4220, p < 
0.0129). This implies, that where albumin predicts FSGS, β2M confirms the presence of FSGS. Other 
studies indicated, both urinary albumin and β2M excretion may be used as markers for kidney or 
tubular diseases (Peterson et al., 1969, Tomlinson et al., 1997).   
In relation to albumin and Cystatin C we found that there was a significant correlation (r = 0.6761, p 
< 0.0001). This implies, that where albumin predicts FSGS, Cystatin C confirmed the presence of 
FSGS. Similar findings by Aygun et al, reported that as GFR decreases, there would be an increase in 
both Cystatin C and albumin. However, this study was conducted in children with sickle nephropathy 
(Aygun et al., 2011). Similarly, Nejat et al observed an inverse relationship between albumin & 
Cystatin C with eGFR (Nejat et al., 2011, Thielemans et al., 1994). 
Under normal physiological conditions, β2M is continuously produced by the body, and is eliminated 
mainly by the kidney (Wibell, 1978). After filtering through the glomerulus, these low molecular 
weight proteins are almost totally reabsorbed into the renal tubules where they are broken down by 
lysosomes of the renal  tubular cells, and finally excreted into the urine   (Wibell, 1978, Hong and 
Lim, 2012). In tubular disorders this process is impaired, and urinary excretion of β2M is increased 
(Hong and Lim, 2012). An increased serum creatinine level, indicating kidney impairment, is a 
measurement of the function of different compartments of the kidney. But an increase in β2M in the 
urine reflects proximal tubular injury (Zeng et al., 2014). The presence of β2M proteins in the urine 
demonstrates an essential defect in proximal tubules, and it may manifest in conditions of 
parenchymal damage or lack of capacity to reabsorb due to overload (Ferguson et al., 2008).  
In our study, β2M expression was significantly different, being upregulated in the HIVAN group 
compared to HIV negative control group. This observation concurred with previous reports of an 
increase in β2M of children diagnosed with HIVAN and HIV – Hemolytic Uremic Syndrome (Soler-
García et al., 2009a). On the other hand, elevated concentrations of β2M was noted in HIV positive 
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children who were on a treatment regimen containing Tenofovir (Papaleo et al., 2007). Individuals on 
HAART, particularly those that include Tenofovir, for extensive periods of time, may encounter renal 
complications such as tubular dysfunction (Gatanaga et al., 2006).  
Urinary β2M concentrations, in our study were elevated in children with idiopathic FSGS compared to 
HIV positive and negative controls, albeit non significant.  Moreover, as early as 1986, an increase in 
urinary β2M was shown in children with FSGS (Portman et al., 1986). Likewise, a study by Kim and 
Lim, reported similar findings of higher levels of β2M in children with FSGS (Kim and Lim, 2007). 
Also high levels of urinary β2M occur in children with nephrotic syndrome in comparison with 
healthy controls (Çalişkan et al., 1996).  Elevated β2M strongly correlated with proximal tubular 
injury in adults, with a high sensitivity of 86.3% (Zeng et al., 2014). 
Overall, the β2M concentrations were high in urine of children with regards to HIV status and FSGS 
in comparison with controls. Despite a low molecular weight of β2M, glomerular damage impacts on 
the movement of β2M across the glomerular basement membrane. Glomerular damage may be as a 
consequence of kidney infection, chronic kidney failure and various connective tissue disorders. Since 
the kidney is unable to reabsorb β2M back into the blood stream, it is possible that they are excreted 
into the urine due to lack of tubular reabsorbption capacity (Sonkar and Singh, 2008).  
Like β2M, Cystatin C is a plasma protein with a low molecular weight that are reabsorbed and 
catabolised by the proximal tubules. Hence, under normal physiological conditions, low concentration 
of Cystatin C is observed in urine but it remains stable in the blood stream (Deyà-Martínez et al., 
2016). Cystatin C proteins are known to protect tissues and cells from damage due to intracellular 
enzymes released from cell apoptosis or malignant cells (Deyà-Martínez et al., 2016). Studies show 
that Cystatin C is a better alternative marker to assess kidney function (Shlipak et al., 2013).   
In our study, a statistically significant increase of the expression of Cystatin C in urine was observed 
in idiopathic FSGS compared to HIV positive and negative controls. Similarly, study in adults by 
Conti et al, reported a high significant difference (p < 0.0001) of urinary Cystatin C in patients with  
tubular disease (Conti et al., 2006).  
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In our study, we reported a low significant urinary cystatin C expression in the HIVAN group 
compared to the idiopathic FSGS group.  A study focusing on growth factors as biomarkers for 
HIVAN prediction in children reported a significant difference of cystatin C (p < 0.05) in children 
with renal disease (Soler-García et al., 2009b). However, when  kidney injury is present, the levels of 
cystatin C may increase (Deyà-Martínez et al., 2016). In our study it is plausible that cystatin C levels 
may be affected by HAART regimen or other medication, viral load and other systemic infection. 
Hence a higher concentration of cystatin C was expected in the HIV positive study group. 
Overall the idiopathic FSGS study population demonstrated elevated concentrations of cystatin C in 
comparison with the other groups. Irrespective of HIV status and FSGS, urinary and serum cystatin C 
concentrations are known to be closely linked to kidney function and, in individuals with kidney 
impairment, these proteins are elevated (Robles et al., 2017). 
Alternatively, and unrelated to our study, it has been suggested that  serum cystatin C  may be used an 
alternative biomarker for further assessment of kidney disease regardless of HIV status (Randers et 
al., 1998).  Herrero-Morin et al, also affirm that serum cystatin C  could possibly be used as a 
biomarker for GFR (Herrero-Morín et al., 2007).   
We found that there was a significant correlation between β2M and cystatin C in FSGS (r = 0.6596, p 
< 0.0001). This implies, that β2M may be used as a predictor of FSGS and cystatin C as a 
confirmatory test or vice versa. A previous study reported that increased urinary cystatin C and β2M 
could be diagnostic of glomerular injury, but was observed in rats with drug induced glomerular 
injury. (Dieterle et al., 2010, Nejat et al., 2011).  Similarly Behairy et al, (2017), observed cystatin C 
and β2M as specific and sensitive markers of screening tubular and glomerular dysfunction in children 
with βeta thalassemia (Behairy et al., 2017). Similarly, a correlation was found in a cohort of HIV 
infected children, by Deyaz et al, where β2M was directly related to cystatin C and GFR was inversely 
related to cystatin C (Deyà-Martínez et al., 2016).  
There were several confounding factors in our study. Firstly, the small sample size may have 
prevented cystatin C reaching a statistical significance. Secondly viral load and the presence of 
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systemic infection was not documented in all children, hence we were not able to correlate our data 
with the severity of HIV infection or other systemic co-infection. Furthermore, since HAART is 
standard of care in South Africa, its nephrotoxic effects may have confounded protein expression in 
the urine. Also, further investigations should also consider an assessment of nutritional state. 
Urinary biomarkers need to have certain characteristics that make them suitable for use in evaluating 
kidney disease.  They should be cost effective, so that they may be easily available in a resource poor 
environment. Also these biomarkers should have high specificity and high sensitivity for accurate 
diagnostic purposes. Further, they should be able to be of prognostic value.  
Finally, this study demonstrates significantly high concentrations of Cystatin C expression, however, 
β2M was significantly different between HIVAN in comparison with the healthy controls only. 
Therefore urinary Cystatin C proteins may be considered suitable biomarker for non invasive testing 
in the early detection of idiopathic and HIV – associated FSGS in paediatric subjects. 
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